Elamipretide restores aged oocyte quality and female fertility by activating vitamin B6-VEGF axis.

Female reproductive aging is the most critical determinant of declining fertility, primarily due to the progressive deterioration of oocyte quality. This age-related decline in oocyte health leads to significant challenges, including poor embryo development, increased miscarriage rates, and ultimately, reduced live birth rates. Despite the recognition of this pervasive issue, highly effective strategies to reverse ovarian aging and substantially improve oocyte quality in older individuals remain elusive. Understanding novel mechanisms and identifying compounds that can preserve ovarian function and enhance oocyte health are therefore crucial for addressing the growing challenge of age-related infertility. Elamipretide, a known mitochondrial-targeting peptide, offers a promising therapeutic avenue due to its established role in improving mitochondrial function.